Bristol-Myers Squibb Co.
Here’s whether Bristol-Myers Squibb Co. (BMY) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 51 — healthy momentum range; strong 1-year return of +19.7%; rising volume confirms the move (1.16x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.64% over 10 days); 3-month momentum negative (-5.5%). Currently 8.9% off its 52-week high. Score: +2/7.
BMY is holding above its long-term 200-day MA ($53.21) but has slipped below the 50-day MA ($58.02), pointing to short-term weakness in an otherwise intact trend. An RSI of 51.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +19.7% compares to +24.4% for SPY (trailed the market by 4.7%).